Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000154
Chunk: 34

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 34
---
 |
| Proceeds from the settlement of cross currency interest rate swaps related to bonds and loans |     |     |       |                                      |   46,880 |     |     |        — |
| Acquisition of treasury shares                                                                |     |     |       |                                      |   -1,882 |     |     |  -51,603 |
| Interest paid                                                                                 |     |     |       |                                      |  -42,298 |     |     |  -52,296 |
| Dividends paid                                                                                |     |     |       |                                      | -147,309 |     |     | -154,082 |
| Repayments of lease liabilities                                                               |     |     |       |                                      |  -23,375 |     |     |  -22,318 |
| Other, net                                                                                    |     |     |       |                                      |   -9,120 |     |     |   -5,476 |
| Net cash from (used in) financing activities                                                  |     |     |       |                                      |  206,336 |     |     | -226,881 |
| Net increase in cash and cash equivalents                                                     |     |     |       |                                      |  425,779 |     |     |  285,444 |
| Cash and cash equivalents at the beginning of the year                                        |     |     |       |                                      |  457,800 |     |     |  385,113 |
| Effects of exchange rate changes on cash and cash equivalents                                 |     |     |       |                                      |  -24,564 |     |     |   10,929 |
| Cash and cash equivalents at the end of the period                                            |     |     |       |                                      |  859,015 |     |     |  681,486 |

<div align='center'>See accompanying notes to condensed interim consolidated financial statements.

- 30 -</div>

Translation for reference purpose only

### Notes to Condensed Interim Consolidated Financial Statements

#### 1. Reporting Entity
Takeda Pharmaceutical Company Limited (the “Company”) is a public company incorporated in Japan. The Company and its subsidiaries (collectively, “Takeda”) is a global, values-based, R&D-driven biopharmaceutical company with a diverse portfolio, engaged primarily in the research, development, production and global commercialization of pharmaceutical products. Takeda’s principal pharmaceutical products include medicines in the following key business areas: Gastroenterology (“GI”),